Valneva receives first marketing authorization for Ixchiq vaccine in a chikungunya endemic country
Valneva SE announced that the Brazilian Health Regulatory Agency (ANVISA) approved Ixchiq vacccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of… read more.